- Home
- HRTX vs SERA Comparison
HRTX vs SERA Comparison
Compare HRTX & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- SERA
- Stock Information
- Founded
- HRTX 1983
- SERA 2008
- Country
- HRTX United States
- SERA United States
- Employees
- HRTX N/A
- SERA N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- SERA Precision Instruments
- Sector
- HRTX Health Care
- SERA Health Care
- Exchange
- HRTX Nasdaq
- SERA Nasdaq
- Market Cap
- HRTX 229.7M
- SERA 208.7M
- IPO Year
- HRTX 1987
- SERA 2021
- Fundamental
- Price
- HRTX $1.63
- SERA $6.64
- Analyst Decision
- HRTX Strong Buy
- SERA
- Analyst Count
- HRTX 3
- SERA 0
- Target Price
- HRTX $5.67
- SERA N/A
- AVG Volume (30 Days)
- HRTX 1.6M
- SERA 153.6K
- Earning Date
- HRTX 03-11-2025
- SERA 03-19-2025
- Dividend Yield
- HRTX N/A
- SERA N/A
- EPS Growth
- HRTX N/A
- SERA N/A
- EPS
- HRTX N/A
- SERA N/A
- Revenue
- HRTX $137,737,000.00
- SERA $94,000.00
- Revenue This Year
- HRTX $13.10
- SERA N/A
- Revenue Next Year
- HRTX $18.76
- SERA $4,263.64
- P/E Ratio
- HRTX N/A
- SERA N/A
- Revenue Growth
- HRTX 12.13
- SERA N/A
- 52 Week Low
- HRTX $1.04
- SERA $4.98
- 52 Week High
- HRTX $3.93
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- HRTX 54.36
- SERA 40.96
- Support Level
- HRTX $1.46
- SERA $6.41
- Resistance Level
- HRTX $1.71
- SERA $6.79
- Average True Range (ATR)
- HRTX 0.09
- SERA 0.55
- MACD
- HRTX 0.00
- SERA -0.19
- Stochastic Oscillator
- HRTX 48.65
- SERA 22.59
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.